Phase III X-TOLE2 data support azetukalner filing in focal onset seizures
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Cenobamate
DrugRelated News
Roche to Invest $478M in Korea Clinical Trials; Pre-Approval Deals Signal Market Strength
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06453213 |
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT04557085 |
Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS |
COMPLETED | PHASE3 |
| NCT03961568 |
Cenobamate Open-Label Extension Study for YKP3089C025 |
COMPLETED | PHASE3 |
| NCT03678753 |
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures |
COMPLETED | PHASE3 |